2022 World Conference on Lung Cancer (ePosters)-EP05.02-005. Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?

EP05.02-005. Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?

Pdf Summary

The study investigated the safety and effectiveness of neoadjuvant treatment in locally advanced lung cancer. A total of 105 patients who underwent lung resection after neoadjuvant therapy were included in the analysis. The different treatment modalities analyzed were chemotherapy (CT) only, chemotherapy and radiotherapy (CT+RT), and chemotherapy and immunotherapy (CT+ImT). <br /><br />The results showed that the major pathological response (MPR) rate was highest in the CT+RT and CT+ImT groups compared to the CT-only group. Specifically, the MPR rate was 21.1% in the CT group, 64.1% in the CT+RT group, and 64.7% in the CT+ImT group. <br /><br />In terms of complications, the CT+RT group had a major complication rate of 12.9%, while no major complications were observed in the CT+ImT group. <br /><br />Survival data showed that the two-year survival rate was highest in the CT+ImT group, with 100% survival. The CT group had a two-year survival rate of 81.3%, and the CT+RT group had a rate of 67.5%. <br /><br />Based on these findings, the study concluded that adding immunotherapy to chemotherapy instead of radiotherapy provides a similar major pathological response in patients but with safer follow-up and possibly longer survival. However, the authors note that the survival data are based on short-term follow-up, as the combination of immunotherapy and chemotherapy has only been used in their center for the past two years. Further research and longer-term follow-up are needed to fully assess the safety and effectiveness of immunotherapy in neoadjuvant treatment for lung cancer.

Asset Subtitle

Ezgi Cesur

Meta Tag

Speaker Ezgi Cesur

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

neoadjuvant treatment

locally advanced lung cancer

lung resection

chemotherapy

radiotherapy

immunotherapy

major pathological response

complications

survival rate

short-term follow-up